
|Videos|July 5, 2017
Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain Metastases
Author(s)Rachel A. Freedman, MD, MPH
Rachel A. Freedman, MD, MPH, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.



















